Expression of MAGE‐1 Gene by Esophageal Carcinomas

Toh, Yuji; Yamana, Hideaki; Shichijo, Shigeki; Fujita, Hiromasa; Tou, Uhi; Sakaguchi, Minako; Kakegawa, Teruo; Itoh, Kyogo

doi:10.1111/j.1349-7006.1995.tb02458.x

Cited by 19 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This high expression frequency and the associated strong immununoreactivity can be explained by the use of a poly‐MAGE antibody detecting 7 members of the MAGE‐A family. Previous studies have shown that at least 1 member of the MAGE‐A gene family is expressed in 34 to 84%7, 13, 14, 15, 16 of the examined esophageal tumors. In most of the studies, including ours, MAGE‐A protein expression rate is lower than MAGE‐A mRNA expression rate 9, 10.…”

Section: Discussionmentioning

confidence: 95%

Heterogeneous expression of GAGE, NY‐ESO‐1, MAGE‐A and SSX proteins in esophageal cancer: Implications for immunotherapy

Akçakanat

Kanda

Tanabe

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Cancer/testis antigens (CTAs) elicit immune response in cancer patients and are therefore targets of immunotherapy. Current information on CTA expression is primarily based on mRNA assays and little is known about their expression at the protein level. The objectives of our study are to analyze GAGE, NY-ESO-1, MAGE-A and SSX protein expression in esophageal cancer and to correlate their expression patterns with clinicopathologic parameters and survival. We examined CTA protein expression in 213 patients with esophageal cancer by immunohistochemistry. Antigen-positive tumors were evaluated once and antigen-negative tumors were evaluated 3 times by examining different parts of the cancer specimen. GAGE, NY-ESO-1 and MAGE-A were heterogeneously expressed in 42 (20%), 44 (21%) and 111 (52%) tumors, respectively, whereas SSX expression was not detected. Of the 126 (59%) patients expressing CTAs, 70 (33%) expressed 1, 41 (19%) expressed 2 and 15 (7%) expressed 3 antigens. The expression of MAGE-A was correlated with those of GAGE (p50.001) and NY-ESO-1 (p50.002), and the expression of GAGE was correlated with that of NY-ESO-1 (p50.002). One hundred fifty-six (79%) sections were positively stained in the first evaluation, whereas 37 (19%) and 4 (2%) positive sections were identified in the second and third evaluations, respectively. Particularly, MAGE and GAGE expression showed overlaps. GAGE, NY-ESO-1 and MAGE-A protein expression was not correlated with the disease progression, TNM factors or survival. The detection of immunonegative cells in every specimen suggests addition of other drugs such as 5-aza-2 0 -deoxycytidine to increase the therapeutic effect of CTA-specific cancer vaccines. ' 2005 Wiley-Liss, Inc.Key words: tumor antigens; immunohistochemistry; prognosis Esophageal cancer is a relatively common and highly malignant neoplasm. After curative surgical resection, the 3-year survival rate remains low at 36 to 40%.

show abstract

Section: Discussionmentioning

confidence: 95%

Heterogeneous expression of GAGE, NY‐ESO‐1, MAGE‐A and SSX proteins in esophageal cancer: Implications for immunotherapy

Akçakanat

Kanda

Tanabe

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…In malignant melanoma, MAGE protein expression analyzed immunohistochemically with mAb 57B has been shown to correlate only with lymphocytic infiltrates, while no correlation was found with any other prognostic parameter. 47 On an mRNA level, correlation between CT antigen expression and tumor stage has been reported in several tumors such as renal cell carcinoma, 48 bladder 49 and esophageal carcinoma, 50 and melanoma. 51 This association has not been demonstrated in others: head and neck carcinoma, 52 seminoma 18 stomach, 53 or colon.…”

Section: Discussionmentioning

confidence: 99%

Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray

et al. 2005

View full text Add to dashboard Cite

Cancer-testis (CT) antigens are expressed in a variety of malignant tumors, but in normal adult tissue, they are only expressed in testicular germ cells. Owing to this tumor-associated expression pattern, these antigens are of major interest as potential targets for immunotherapy and possibly for diagnostic purposes. This study was performed to analyze the expression of four CT antigens, NY-ESO-1, MAGE-A3, MAGE-A4, and CT7/MAGE-C1, in endometrial carcinoma using immunohistochemistry, and to correlate expression with histologic subtypes, grade, and expression of WT1 and p53. Formalin-fixed paraffin-embedded tissues of 130 endometrial carcinomas of the following types and grades were analyzed using a tissue microarray: 85 endometrioid carcinomas (FIGO grade 1, 39; grade 2, 11; and grade 3, 35), 18 papillary serous carcinomas, 12 clear cell carcinomas, 13 malignant mixed mullerian tumors, one mucinous adenocarcinoma, and one undifferentiated carcinoma. The following anti-CT monoclonal antibodies/antigens were studied by immunohistochemistry: monoclonal antibody ES121/NY-ESO-1, monoclonal antibody M3H67/MAGE-A3, monoclonal antibody 57B/ MAGE-A4, and monoclonal antibody CT7-33/CT7. The CT expression data were compared to WT1 and p53 protein expression as analyzed in a previous study. Positive staining with anti-CT monoclonal antibodies was graded as follows: focal, o5% positive cells; 1 þ , 5-25% cells; 2 þ , 26-50% cells; 3 þ , 51-75%; and 4 þ , 475% cells. The 3 þ and 4 þ staining patterns were considered homogeneous patterns of potential clinical significance and were scored positive for statistical analysis. In low-grade tumors, the most immunoreactivity was seen with mAb M3H67 but little labeling was observed with the other monoclonal antibodies. In high-grade tumors, monoclonal antibodies M3H67 (25%), 57B (23%), and CT7-33 (20%) showed the highest reactivity, while ES121 showed the lowest immunoreactivity (6%). The staining pattern was mostly heterogeneous. Statistical significance was found solely for the correlation of monoclonal antibody 57B staining and p53 expression. No correlation was found for any anti-CT monoclonal antibody staining and clinical stage or for anti-CT staining and WT1 expression. CT antigens CT7, MAGE-A3 and MAGE-A4, but not NY-ESO-1, are expressed in high-grade endometrial carcinomas, and expression of MAGE-A4 is correlated with the presence of overexpressed p53.

show abstract

“…Moreover, we showed that higher levels of MAGE-A4 expression correlated with advanced tumor stage, which is consistent with previous reports. [36][37][38][39] The exact mechanism by which expression of MAGE-A4 and other CTAs results in poor clinical outcome is not well described. 40 The precise role that CT antigens might play in cancer cell biology has yet remained to be clarified.…”

confidence: 99%

Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy

Forghanifard

Gholamin²,

Farshchian³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Expression of MAGE‐1 Gene by Esophageal Carcinomas

Cited by 19 publications

References 10 publications

Heterogeneous expression of GAGE, NY‐ESO‐1, MAGE‐A and SSX proteins in esophageal cancer: Implications for immunotherapy

Heterogeneous expression of GAGE, NY‐ESO‐1, MAGE‐A and SSX proteins in esophageal cancer: Implications for immunotherapy

Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray

Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy

Contact Info

Product

Resources

About